Astex Therapeutics Limited

Institute of Cancer Research: Royal Cancer Hospital (the)

The Institute of Cancer Research: Royal Cancer Hospital

Domainex Limited

Anna Hopkins

Christopher Norbert Johnson

Christopher William Murray

Gordon Saxty

Steven Howard

Gianni Chessari

Ildiko Maria Buck

Christopher Lord

Dan Niculescu-Duvaz

James Edward Harvey Day

Alan Ashworth

Trevor Robert Perrior

Mark Richard Stewart

Kerry Jenkins

Gary Karl Newton

Lee William Page

Rebekah Elisabeth Key

Rehan Aqil

Stuart Firth-Clark

Ashley Nicholas Jarvis

Melanie Jayne Bayford

Raymond John Boffey

Roderick Alan Porter

Philip Alan Skone

Richard James Rowland Elliott

Gabriel Negoita-giras

James Edward Day

Stuart Richard Crosby

The invention relates to new bicyclic heterocycle compounds, to pharmaceutical compositions comprising the compounds and to the use of the compounds in the treatment of diseases, e.g. cancer.

Bicyclic heterocycle compounds and their uses in therapy

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc. 

3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use

Growing community of inventors

Cambridge, United Kingdom

Anna Hopkins